Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.
about
Modeling biological rhythms in failure time data.Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study.Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis.Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen).Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.Cancer chronotherapy.Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic OBiweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.Oxaliplatin (L-OHP): a new reality in colorectal cancer.Oxaliplatin in practiceMulticenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group.A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma.Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study.Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.Hypersensitivity reactions related to oxaliplatin (OHP).Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancerOxaliplatin in the treatment of colorectal cancer.Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma.A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.Oxaliplatin: a review of approved uses.Making a case for programmable pumps over fixed rate pumps for the management of fluctuations in chronic pain and spasticity: a literature review.Platinum-based compounds for the treatment of metastatic breast cancer.Oxaliplatin for the treatment of ovarian cancer.Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.Chronobiology. Implications for cancer chemotherapy.A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors.Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancerCircadian variation in O6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects.Chronotherapy of colorectal cancer.
P2860
Q33262921-C9FE4D01-194B-4AB7-8BC6-C438C074A51AQ33358104-AE1D8C07-998B-45B0-8783-A3209E67455AQ33366008-7C358933-BB13-45DA-9030-0D4BBD44733AQ33373017-1FE6A6B2-DF5E-4F8F-8180-6ED0B552028EQ33376718-900C2898-30CF-4629-85A1-EA57B0ED56A2Q33383287-EE100403-3F36-431E-9D79-6DC264CA1A98Q33389036-0B01018E-CD1C-4DFA-85D5-D1E4DD391FFFQ33393039-0C3BF149-1A95-4681-9DB7-FEC9782DD523Q33400294-E128879B-E3F9-4499-A7BC-4A8E03BF1EEFQ33403870-4BB12B43-822F-4D69-91CB-430709911608Q33742395-1E84E977-AEFC-4FDF-8857-DA1AEE32A38BQ33879736-9B6E218B-EE43-45B0-BC90-25C107B10E28Q34504536-C6826679-77E7-443F-A344-316413490128Q34565268-569BA274-06E5-42DB-A44D-56D60C5FD81DQ34594956-7FB361AF-E1D3-4DE2-B650-85FC61187939Q36291590-03ECCEAF-93A9-4F51-BCDD-92CABED50C2BQ36291603-8E15C3EE-22F0-49A3-9C44-64DBE031FD2BQ36459767-E758E696-CAEB-4AB3-8AA6-08DF99493559Q36594055-B067B4E6-54E0-4CF7-8B81-FB90E4182004Q36615060-35D32821-9752-4C6C-AF14-C47874BEDC19Q36623730-81886925-06C5-47CA-B5CB-9FCDDAC5496CQ36626112-F14A7845-0557-4130-AF71-8E981DDAED63Q36636872-EAE97B2E-E3FA-4837-8609-960F9F3157EFQ36671350-98A39EBC-7379-4AC3-86EB-875BEC786EF6Q36671857-D96DCC2A-5C3F-4053-8EE5-F3955DD6FB0AQ36788436-70CDE278-77CD-4F70-8CA4-9FBEDC058E8DQ36936011-66F6D62E-EDA0-4B82-833A-ED1C4E4B11CFQ37134006-8595003C-8D30-49A1-8F89-BCC210106FF2Q37383249-7C68E38B-185B-49BE-A994-AAF5AA390FC5Q37965616-72EE99FC-0F31-4EE3-91AE-B314DC1010B5Q37965990-66B52F42-BB90-49C4-A776-EEA31D051F78Q37976172-4C7A41AA-88E3-4681-92B8-88A06BD3D199Q38540596-31BAE0F5-482C-42B5-9D2C-7D2577041505Q38650019-8CFB7CA5-E75F-45A7-A4B0-F20346CC20C1Q39566084-12205E19-BABF-4880-84E6-935ECDA19825Q40405359-A8CB9BD3-4AE7-4D30-A7FA-8BE99CCBF755Q40627120-B08EDE94-0563-41C1-8C59-740C2DB0EBB2Q42032242-77264FB6-9DAF-4A45-B914-3B2C6ED31FE4Q43517192-535EE6E8-F870-4150-A5E0-8B30BDF1B512Q43965422-54B3267D-BD8C-4BA6-A870-D00EDF946468
P2860
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Phase I trial of 5-day continu ...... e compared with constant rate.
@en
type
label
Phase I trial of 5-day continu ...... e compared with constant rate.
@en
prefLabel
Phase I trial of 5-day continu ...... e compared with constant rate.
@en
P2093
P356
P1476
Phase I trial of 5-day continu ...... e compared with constant rate.
@en
P2093
Caussanel JP
P304
P356
10.1093/JNCI/82.12.1046
P407
P577
1990-06-01T00:00:00Z